| [1] |
Filho A M, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates:data sources,methods,and a snapshot of the cancer burden worldwide[J]. Int J Cancer, 2025, 156(7):1336-1346.
|
| [2] |
Li D, Wang A, Wang X, et al. The TEAD4-DYNLL1 axis accelerates cell cycle progression and augments malignant properties of lung adenocarcinoma cells[J]. Eur J Med Res, 2025, 30(1):221.
|
| [3] |
Annette L. Fighting the good fight:Europe's beating cancer plan[J]. Impact, 2023, 2023(3):4-5.
|
| [4] |
张苗苗, 段东奎, 余春, 等. miR-924、SLC1A5在肺癌组织中的表达及其在预后评估中的价值[J]. 检验医学, 2024, 39(1):13-18.
|
| [5] |
Cui Q, Peng L, Wei L, et al. Genetic variant repressing ADH1A expression confers susceptibility to esophageal squamous-cell carcinoma[J]. Cancer Lett, 2018, 421:43-50.
|
| [6] |
Ma J, Shi Y, Lu Q, et al. Inflammation-related gene ADH1A regulates the polarization of macrophage M1 and influences the malignant progression of gastric cancer[J]. J Inflamm Res, 2024, 17:4647-4665.
|
| [7] |
Zhang Y, Jiang H H, Wang Z Y, et al. Alcohol dehydrogenase 4 is a TP53-associated gene signature for the prediction of prognosis in hepatocellular carcinoma[J]. Oncol Lett, 2022, 25(1):3.
|
| [8] |
Chen C, Guo S, Chai W, et al. A comprehensive genome-based analysis identifies the anti-cancerous role of the anoikis-related gene ADH1A in modulating the pathogenesis of breast cancer[J]. Mol Genet Genomics, 2024, 299(1):108.
|
| [9] |
Cymbaluk-poska A, Chudecka K, Chudecka-gaz A, et al. Importance of potential new biomarkers in patient with serouse ovarian cancer[J]. Diagnostics(Basel), 2021, 11(6):1026.
|
| [10] |
Liu T, Zhang F, Feng Y, et al. Alcohol-metabolizing enzymes,liver diseases and cancer[J]. Semin Liver Dis, 2025, 45(1):99-113.
|
| [11] |
Liming S, Guangzhi Z, Hao S, et al. Identification of alcohol dehydrogenase as a potential prognostic marker in HBV-related hepatocellular carcinoma[J]. Int J Clin Exp Med, 2017, 10(3):4457-4472.
|
| [12] |
Guo E, Wei H, Liao X, et al. Prognostic value of alcohol dehydrogenase mRNA expression in gastric cancer[J]. Oncol Lett, 2018, 15(4):5505-5516.
|
| [13] |
Yin D, Zhang Y, Li H, et al. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma[J]. Clin Respir J, 2023, 17(12):1301-1315.
|
| [14] |
戚永超, 缪劲, 张黄梦捷. 血清IL-11、IL-17与LUAD患者术后生存期的相关性[J]. 临床肺科杂志, 2023, 28(6):838-843.
|
| [15] |
周玉飞, 李云辉, 李冰熠, 等. C反应蛋白/白蛋白比值和系统免疫炎症指数与浆液性卵巢癌患者临床病理特征和预后的关系[J]. 检验医学, 2024, 39(4):363-368.
|
| [16] |
Wang Y, Huan C, Wang G, et al. The inflammation burden index can predict the cardiac injury following antitumour therapy in lung cancer patients with diabetes[J]. Sci Rep, 2025, 15(1):11291.
|
| [17] |
黄文棋. 人类乙醇脱氢酶1A的生物信息学分析及在肺癌中的功能分析[D]. 广州: 南方医科大学, 2020.
|
| [18] |
Bhatt D K, Gaedigk A, Pearce R E, et al. Age-dependent protein abundance of cytosolic alcohol and aldehyde dehydrogenases in human liver[J]. Drug Metab Dispos, 2017, 45(9):1044-1048.
|
| [19] |
Behrens C, Rocha P, Parra E R, et al. Female gender predicts augmented immune infiltration in lung adenocarcinoma[J]. Clin Lung Cancer, 2021, 22(3):e415-e424.
|
| [20] |
Zahid K R, Yao S, Khan A R R, et al. mTOR/HDAC1 crosstalk mediated suppression of ADH1A and ALDH2 links alcohol metabolism to hepatocellular carcinoma onset and progression in silico[J]. Front Oncol, 2019, 9:1000.
|
| [21] |
Zhang C, Rasool A, Qi H, et al. Comprehensive analysis of the first complete mitogenome and plastome of a traditional Chinese medicine Viola diffusa[J]. BMC Genomics, 2024, 25(1):1162.
|
| [22] |
Wang X, Yan G, Zhang X, et al. LNX1-AS2 as a key prognostic and immunotherapy response biomarker for lung adenocarcinoma[J]. Curr Med Chem, 2025, 32(35):7894-7905.
|
| [23] |
Mao G, Mu Z, Wu D. Exosome-derived miR-2682-5p suppresses cell viability and migration by HDAC1-silence-mediated upregulation of ADH1A in non-small cell lung cancer[J]. Hum Exp Toxicol, 2021, 40(12 suppl):S318-S330.
|